, Rhizomucor sp. and Mucor sp. Interestingly, that in European study most frequently isolated were also fungi of the genus Rhizopus, but the second most common pathogens were Mucor species,[2, 7] which Crizotinib supplier were identified only in one patient in St. Petersburg. The observations of Skiada et al. demonstrated that surgical treatment was used in 40% of patients.[2] In St. Petersburg, surgical interventions were subjected to 52% of patients. According

to the European study, the main used antifungal agents were amphotericin B and its derivatives (39%) two-thirds of which were lipid complexes of amphotericin B.[2] We also frequently used amphotericin B and its derivatives and at the same time 59% of patients received posaconazole. In 52% patients, we used a combination of echinocandins (mostly caspofungin) and different forms of amphotericin B for treatment of mucormycosis. Echinocandins

have minimal activity against mucormycetes in vitro.[7] At the same time, animal models were established the activity of the drugs in combination therapy of mucormycosis.[9, 13] Later appeared publications about successful use of echinocandins in combination with other agents for mucormycosis treatment.[12, 13] Our experience showed the effectiveness of this approach. Despite the use of new antifungal agents survival rate of patients with mucormycosis Selleck CAL 101 and haematological malignancies is low. Thus, according to Skiada et al. [2] survival rate of patients with mucormycosis who underwent haematopoietic stem cell transplantation was 24%. As reported by Pagano et al. [10] the survival rate of haematological patients with mucormycosis was 13%. According to the data of our register, the 12-week survival rate for oncohaematological patients after treatment in 2011 was 27%, in 2012 it was 37% and in 2013 50%.[14, 15] No conflict of interest. “
“Stachybotrys eucylindrospora was characterised as a new species in 2007, and we present the first

report of this organism isolated from foreign material recovered from a patient. It is probable that isolates of this species have been previously identified as Ixazomib cost either Stachybotrys chartarum or Stachybotrys cylindrospora. “
“Candida guilliermondii is an uncommon isolate throughout most of the world, the behaviour of which as an environmental fungus, a human saprophyte and an agent of serious infections has been emphasised over the years. Notably, illnesses caused by this pathogen mostly involve compromised cancer hosts and commonly lead patients to unfavourable outcomes. It is of concern that the yeast may acquire or inherently express reduced in vitro sensitivity to all antifungal classes, although widespread resistance has not yet been described, and poor correlation exists between MICs and clinical outcome.